Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of MLN1202 in Healthy Japanese and Caucasian Males
NCT02426021Phase 1Withdrawn
- Sponsor
- Takeda
- Start
- Apr 2015
- Primary completion
- Nov 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of plozalizumab in atherosclerosis (10 cohorts), sponsored by Takeda. Primary endpoint: Number of Participants Reporting One or More Treatment-emergent Adverse Events. Planned start Apr 2015; status: withdrawn.
02
Drugs
plozalizumab
03
Conditions
atherosclerosis
Beyond the preview
Go deeper on NCT02426021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02426021.